{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:08:10Z","timestamp":1792814890898,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euf.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T21:05:10Z","timestamp":1768856710000},"page":"383-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1848-584X","authenticated-orcid":false,"given":"Filippo","family":"Carletti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Tamborino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Turcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Maria","family":"Valenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Alfredo","family":"Morgantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan Bahadir","family":"Haberal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Dal Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Crivellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.01.003_b0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ucl.2016.04.001","article-title":"The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates","volume":"43","author":"Egan","year":"2016","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euf.2026.01.003_b0010","unstructured":"European Association of Urology. Management of non-neurogenic male LUTS. 2025. https:\/\/uroweb.org\/guidelines\/management-of-non-neurogenic-male-luts\/chapter\/introduction."},{"key":"10.1016\/j.euf.2026.01.003_b0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.sxmr.2018.02.003","article-title":"New and emerging technologies in treatment of lower urinary tract symptoms from benign prostatic hyperplasia","volume":"7","author":"Gupta","year":"2019","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.euf.2026.01.003_b0020","unstructured":"Epic Cosmos. https:\/\/cosmos.epic.com\/."},{"key":"10.1016\/j.euf.2026.01.003_b0025","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1055\/s-0041-1731004","article-title":"The Cosmos Collaborative: a vendor-facilitated electronic health record data aggregation platform","volume":"5","author":"Tarabichi","year":"2021","journal-title":"ACI Open"},{"key":"10.1016\/j.euf.2026.01.003_b0030","unstructured":"ICD-10 version:2019. https:\/\/icd.who.int\/browse10\/2019\/en."},{"key":"10.1016\/j.euf.2026.01.003_b0035","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41391-023-00741-8","article-title":"Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study","volume":"27","author":"Kaplan","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2026.01.003_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1287212","article-title":"Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review","volume":"14","author":"He","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.euf.2026.01.003_b0045","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/JU.0000000000001463","article-title":"Surgical reintervention rates after invasive treatment for lower urinary tract symptoms due to benign prostatic syndrome: a comparative study of more than 43,000 patients with long-term followup","volume":"205","author":"Gilfrich","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.01.003_b0050","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00345-020-03512-5","article-title":"Laparoscopic simple prostatectomy vs bipolar plasma enucleation of the prostate in large benign prostatic hyperplasia: a two-center 3-year comparison","volume":"39","author":"Lombardo","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2026.01.003_b0055","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1002\/bco2.483","article-title":"Comparing GreenLight PVP and HoLEP beyond 5 years: a systematic review of long-term functional outcomes and reoperation rates","volume":"6","author":"Yim","year":"2025","journal-title":"BJUI Compass"},{"key":"10.1016\/j.euf.2026.01.003_b0060","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.euf.2021.12.006","article-title":"Long-term reinterventions after thulium laser enucleation of the prostate: 12-year experience with more than 1000 patients","volume":"8","author":"Gr\u00fcne","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.01.003_b0065","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.euf.2024.04.006","article-title":"Benign prostatic hyperplasia surgery: a snapshot of trends, costs, and surgical retreatment rates in the USA","volume":"10","author":"Ditonno","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.01.003_b0070","first-page":"8802","article-title":"Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study","volume":"24","author":"Roehrborn","year":"2017","journal-title":"Can J Urol"},{"key":"10.1016\/j.euf.2026.01.003_b0075","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/JU.0000000000001778","article-title":"Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"206","author":"McVary","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.01.003_b0080","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41391-025-00953-0","article-title":"Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis","volume":"28","author":"Kaplan","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2026.01.003_b0085","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2019.05.003","article-title":"The utilization of benign prostatic hyperplasia and bladder-related medications after a transurethral prostatectomy","volume":"130","author":"Campbell","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euf.2026.01.003_b0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00345-021-03819-x","article-title":"Persistent use of medical therapy after surgery for lower urinary tract symptoms: a retrospective database analysis","volume":"40","author":"Ory","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2026.01.003_b0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1590\/s1677-5538.ibju.2024.0039","article-title":"Long-term functional outcomes and surgical retreatment after thulium laser enucleation of the prostate: a 10-year follow-up study","volume":"50","author":"Manfredi","year":"2024","journal-title":"Int Brazilian J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:29:56Z","timestamp":1785529796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2405456926000027"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.01.003","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year Retreatment and Medication Restart Rates Following Benign Prostate Hyperplasia Treatments: A Nationwide Real-world Analysis Using Epic Cosmos","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}